Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin plus weekly paclitaxel vs placebo plus weekly paclitaxel in previously treated advanced gastric or GEJ adenocarcinoma
jRCT2080222639Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Oct 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Napabucasin + weekly paclitaxel with Placebo + weekly paclitaxel (2 arms). Started Oct 2014; status: completed.
02
Drugs
napabucasin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222639.